• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849

3-methylimidazo[1,2-a]pyridine-6-carbonitrile (CAS No. 952511-46-5): A Comprehensive Overview

The compound 3-methylimidazo[1,2-a]pyridine-6-carbonitrile, identified by its CAS number 952511-46-5, is a heterocyclic organic molecule that has garnered significant attention in the field of pharmaceutical research and development. This compound belongs to the imidazopyridine class, a structural motif known for its diverse biological activities and potential therapeutic applications. The presence of a nitrile group at the 6-position introduces unique electronic and steric properties, making it a valuable scaffold for designing novel bioactive molecules.

In recent years, there has been a growing interest in exploring the pharmacological potential of imidazopyridine derivatives. The structural framework of 3-methylimidazo[1,2-a]pyridine-6-carbonitrile allows for modifications at multiple positions, enabling the synthesis of a wide range of analogs with tailored biological properties. These modifications can be strategically employed to optimize binding affinity, metabolic stability, and pharmacokinetic profiles, thereby enhancing the drug-like characteristics of the compounds.

One of the most compelling aspects of this compound is its potential as an intermediate in the synthesis of more complex pharmacophores. The nitrile group can be further functionalized through various chemical transformations, such as hydrolysis to an amide or reduction to an amine, providing a versatile platform for drug discovery. Additionally, the methyl group at the 3-position can serve as a handle for further derivatization, allowing chemists to explore different chemical spaces and identify novel lead compounds.

Recent studies have highlighted the importance of heterocyclic compounds in medicinal chemistry. Imidazopyridines, in particular, have shown promise in various therapeutic areas, including oncology, inflammation, and central nervous system disorders. The< strong>3-methylimidazo[1,2-a]pyridine-6-carbonitrile (CAS No. 952511-46-5) has been investigated for its potential role as a precursor in the development of small-molecule inhibitors targeting specific biological pathways. For instance, researchers have explored its utility in generating compounds that interact with enzymes involved in cancer cell proliferation and survival.

The synthesis of< strong>3-methylimidazo[1,2-a]pyridine-6-carbonitrile involves multi-step organic reactions that highlight the compound's synthetic accessibility. The process typically begins with the condensation of appropriate precursors under controlled conditions to form the imidazopyridine core. Subsequent functionalization steps introduce the nitrile group and other desired substituents. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to produce larger quantities of this compound for research and development purposes.

The biological activity of< strong>3-methylimidazo[1,2-a]pyridine-6-carbonitrile has been evaluated in various in vitro and in vivo models. Preliminary studies suggest that this compound exhibits promising pharmacological effects across multiple targets. For example, it has been shown to inhibit the activity of certain kinases implicated in tumor growth and metastasis. Additionally, its interaction with other biological receptors and enzymes has been explored, revealing potential therapeutic benefits in conditions such as inflammation and neurodegeneration.

The development of novel drugs relies heavily on the availability of high-quality chemical building blocks like< strong>3-methylimidazo[1,2-a]pyridine-6-carbonitrile. This compound serves as a valuable tool for medicinal chemists seeking to design molecules with improved efficacy and reduced toxicity. By leveraging its structural features and synthetic versatility, researchers can accelerate the discovery process and bring new treatments to patients more quickly.

In conclusion,< strong>3-methylimidazo[1,2-a]pyridine-6-carbonitrile (CAS No. 952511-46-5) represents a significant advancement in pharmaceutical chemistry. Its unique structural properties and potential biological activities make it a compelling candidate for further investigation. As research continues to uncover new therapeutic applications for imidazopyridine derivatives, this compound is poised to play a crucial role in the development of next-generation medicines.

• 34165-15-6(3,7-dimethyl-Imidazo[1,2-a]pyridine)
• 1338497-92-9(1-methyl-Imidazo[1,2-a]quinoline-4-carbonitrile)
• 1284210-50-9(3,8-dimethyl-Imidazo[1,2-a]pyridine)
• 1313726-32-7(3-(hydroxymethyl)imidazo1,2-apyridine-6-carbonitrile)
• 102308-96-3(2,6-dimethyl-imidazo[1,2-a]pyridine)
• 78132-62-4(3,6-Dimethylimidazo1,2-Apyridine)
• 881841-28-7(2-Formylimidazo[1,2-a]pyridine-6-carbonitrile)
• 21797-99-9(Imidazo[1,2-a]pyridine-3-carbonitrile,7-methyl-)
• 1167571-42-7(2-ethyl-Imidazo[1,2-a]pyridine-8-carbonitrile)
• 300858-63-3(1-methyl-Pyrido[1,2-a]benzimidazole-4-carbonitrile)